BE637389A
(sv)
*
|
1962-09-13 |
|
|
|
GB1560274A
(en)
*
|
1977-02-28 |
1980-02-06 |
Ici Ltd |
Phenylbut 1-ene derivatives having antiostrogenicactivity
|
US4206234A
(en)
*
|
1977-08-22 |
1980-06-03 |
Imperial Chemical Industries Limited |
Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
|
EP0002097B1
(en)
*
|
1977-08-22 |
1981-08-05 |
Imperial Chemical Industries Plc |
Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
|
HU178253B
(en)
*
|
1979-08-15 |
1982-04-28 |
Gyogyszerkutato Intezet |
Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
|
DE3046719C2
(de)
*
|
1980-12-11 |
1983-02-17 |
Klinge Pharma GmbH, 8000 München |
1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
|
ATE25515T1
(de)
*
|
1983-05-24 |
1987-03-15 |
Bristol Myers Co |
Verfahren zur umwandlung von 1,2-diphenyl-1-(4-(2-dimethylamino-ethoxy)-phen l>-1-buten-e-isomeren zu tamoxifen-hydrochlorid.
|
US4806685A
(en)
*
|
1985-08-05 |
1989-02-21 |
Gyogyszerkutato Inteezet/Pharmaceutical Research Institute |
1,1,2-triphenylpropane and -propene derivatives
|
GB8604528D0
(en)
*
|
1986-02-24 |
1986-04-03 |
Ici Plc |
Therapeutic agents
|
CA1289570C
(en)
*
|
1986-06-16 |
1991-09-24 |
Tetsuji Asao |
1,1,2-triaryl-1-alkene derivatives
|
EP0287690B1
(de)
*
|
1987-04-21 |
1992-09-02 |
HEUMANN PHARMA GMBH & CO |
Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
|
DE3736682A1
(de)
*
|
1987-10-29 |
1989-05-11 |
Klinge Co Chem Pharm Fab |
Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5446203A
(en)
*
|
1992-08-25 |
1995-08-29 |
New York University |
Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
|
US6251920B1
(en)
|
1993-05-13 |
2001-06-26 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
US5770609A
(en)
*
|
1993-01-28 |
1998-06-23 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
US5354861A
(en)
*
|
1992-11-04 |
1994-10-11 |
National University Of Singapore |
2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
DE69435137D1
(de)
*
|
1993-05-13 |
2008-10-16 |
Poniard Pharmaceuticals Inc |
Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
|
TW275584B
(sv)
*
|
1993-06-24 |
1996-05-11 |
Fli Lilly And Co |
|
US5462950A
(en)
*
|
1993-12-21 |
1995-10-31 |
Eli Lilly And Company |
Methods of treating menstrual symptoms and compositions therefore
|
US5451590A
(en)
*
|
1993-12-21 |
1995-09-19 |
Eli Lilly & Co. |
Methods of inhibiting sexual precocity
|
US6417198B1
(en)
*
|
1993-12-21 |
2002-07-09 |
Eli Lilly And Company |
Methods of inhibiting CNS problems in post-menopausal women
|
US5534526A
(en)
*
|
1993-12-21 |
1996-07-09 |
Eli Lilly And Company |
Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
|
GB9326255D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Roussel Lab Ltd |
Medical device for the prevention and treatment of cancer
|
US5650425A
(en)
*
|
1994-04-04 |
1997-07-22 |
Pharmos Corporation |
Permanently ionic derivatives of steroid hormones and their antagonists
|
US5681835A
(en)
*
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
TW398975B
(en)
|
1994-07-22 |
2000-07-21 |
Lilly Co Eli |
Pharmaceutical composition for inhibiting bone loss
|
CA2223595C
(en)
|
1995-06-07 |
2008-08-05 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
|
DE19526146A1
(de)
*
|
1995-07-07 |
1997-01-09 |
Schering Ag |
Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
|
JP2000503315A
(ja)
|
1996-01-20 |
2000-03-21 |
ブラッドフォード・ユニバーシティ |
タモキシフェンおよびその同族体
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
US6083990A
(en)
|
1997-04-02 |
2000-07-04 |
Pharmos Corporation |
Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
|
CA2280181A1
(en)
*
|
1997-02-09 |
1998-08-13 |
Pharmos Corporation |
Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
|
WO1998037892A1
(en)
*
|
1997-02-27 |
1998-09-03 |
Pharmacia & Upjohn Company |
Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
|
GB9715479D0
(en)
*
|
1997-07-23 |
1997-10-01 |
Univ Bradford |
Tamoxifen and analogues thereof
|
EE200000077A
(et)
|
1997-08-15 |
2000-12-15 |
Duke University |
Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
|
TW593256B
(en)
|
1999-11-16 |
2004-06-21 |
Hormos Medical Oy Ltd |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
GB0012291D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Astrazeneca Ab |
Pharmaceutical combination
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
EP1490030B2
(en)
*
|
2002-03-20 |
2010-07-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of angiogenesis inhibitors
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
US7332525B2
(en)
*
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
KR20060040746A
(ko)
*
|
2003-09-19 |
2006-05-10 |
화이자 프로덕츠 인크. |
2-알킬리덴-19-노르-비타민 d 유도체와 에스트로겐효능제/길항제의 조합물을 포함하는 제약 조성물 및 방법
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
JP2007526337A
(ja)
|
2004-03-02 |
2007-09-13 |
アクセルロン ファーマ インコーポレーテッド |
Alk7およびミオスタチン阻害剤ならびにその使用
|
US20050203086A1
(en)
*
|
2004-03-04 |
2005-09-15 |
Pfizer Inc. |
Methods of treatment using an EP2 selective receptor agonist
|
ES2328384T3
(es)
*
|
2004-11-23 |
2009-11-12 |
Warner-Lambert Company Llc |
Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
|
AU2006207325B2
(en)
|
2005-01-21 |
2012-08-16 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
ZA200800907B
(en)
|
2005-07-18 |
2010-04-28 |
Bipar Sciences Inc |
Treatment of cancer
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
KR101505884B1
(ko)
|
2006-05-22 |
2015-03-25 |
호르모스 메디칼 리미티드 |
만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
|
JP5193196B2
(ja)
|
2006-06-02 |
2013-05-08 |
ペア ツリー ウーマンズ ヘルス ケア |
萎縮性膣炎の治療の方法
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
EP2170396B1
(en)
|
2007-08-03 |
2016-12-21 |
Summit Corporation Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
NZ591955A
(en)
|
2007-10-16 |
2011-10-28 |
Repros Therapeutics Inc |
Trans-clomiphene for diabetes mellitus type 2
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
KR20140117457A
(ko)
|
2012-01-31 |
2014-10-07 |
노파르티스 아게 |
Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
|
EP2819676B1
(en)
|
2012-02-29 |
2018-05-30 |
Repros Therapeutics Inc. |
Combination therapy for treating androgen deficiency
|
US9353132B2
(en)
|
2012-03-05 |
2016-05-31 |
Xavier University Of Louisiana |
Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
|
CN103992234B
(zh)
*
|
2014-06-11 |
2016-05-18 |
扬子江药业集团江苏海慈生物药业有限公司 |
一种枸橼酸他莫昔芬e异构体的制备方法
|
AU2016352592B2
(en)
|
2015-11-10 |
2023-04-27 |
Paracrine Therapeutics Ab |
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
|
WO2017120204A2
(en)
|
2016-01-05 |
2017-07-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
WO2018034945A1
(en)
|
2016-08-19 |
2018-02-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
|
US10751345B2
(en)
|
2018-02-21 |
2020-08-25 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
EP3982944A4
(en)
*
|
2019-06-10 |
2023-09-13 |
University of Iowa Research Foundation |
SWELL1 MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER STEATOSIS, IMMUNE DEFICIENCIES, MALE STERILITY AND VASCULAR DISEASES
|
CN114133334A
(zh)
*
|
2021-11-09 |
2022-03-04 |
北京京丰制药(山东)有限公司 |
枸橼酸他莫昔芬的工业化制备工艺
|
EP4230196A1
(en)
|
2022-02-21 |
2023-08-23 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of dystrophinopathies
|
EP4311546A1
(en)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Combination therapy for myopathies
|